Abstract | PURPOSE: PATIENTS AND METHODS: In the initial dose-escalation phase, 25 patients with adenocarcinoma of the breast (AB; 13 patients) or lymphoma (12 patients) were given daniplestim at doses ranging from 0.1 to 3.75 microgram/kg/d plus G-CSF 10 microgram/kg/d. In the randomized phase, 52 patients with AB (27 patients) or lymphoma (25 patients) were randomized within disease categories to the daniplestim dose chosen in the dose-escalation phase plus G-CSF 10 microgram/kg/d (D+G) or placebo plus G-CSF 10 microgram/kg/d (P+G) for up to 7 days. RESULTS: A daniplestim dose of 2. 5 microg/kg/d was chosen for further study because it was hematopoietically active and had an acceptable side-effect profile. In the randomized phase, in patients with AB, D+G was associated with a higher probability (P =.0696) of collecting >/= 2.5 x 10(6) CD34(+) cells/kg and significantly higher circulating CD34(+) cell counts (P =.0498) on days 6 through 9 after the initiation of dosing. The target level was more likely to be reached with additional leukaphereses in the patients given D+G. Patients given P+G did not benefit from additional leukaphereses beyond the first procedure. The type of mobilization did show a trend toward a shorter duration of neutropenia in the D+G group. The adverse events with D+G consisted largely of mild to moderate flu-like symptoms, including headache and fever, and occurred more frequently than with P+G. CONCLUSION:
Daniplestim administered at 2.5 microgram/kg/d is tolerable and active when combined with G-CSF, and the combination may prove more effective than G-CSF alone in promoting the collection of adequate numbers of CD34(+) cells for PBSC infusion in patients with AB.
|
Authors | J F DiPersio, M W Schuster, C N Abboud, J N Winter, V R Santos, D M Collins, J W Sherman, C M Baum |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 18
Issue 14
Pg. 2762-71
(Jul 2000)
ISSN: 0732-183X [Print] United States |
PMID | 10894877
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, CD34
- Antineoplastic Agents
- Interleukin-3
- Peptide Fragments
- Peptides
- Granulocyte Colony-Stimulating Factor
- daniplestim
|
Topics |
- Adenocarcinoma
(immunology, therapy)
- Adult
- Antigens, CD34
- Antineoplastic Agents
(therapeutic use)
- Breast Neoplasms
(immunology, therapy)
- Double-Blind Method
- Drug Administration Schedule
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Hematopoietic Stem Cell Mobilization
- Hematopoietic Stem Cell Transplantation
- Humans
- Interleukin-3
- Lymphocyte Count
- Lymphoma
(immunology, therapy)
- Peptide Fragments
- Peptides
(administration & dosage)
|